Teva Pharmaceutical Industries

TEVA

39.9701.04% ( -0.420 )

Closed: Oct 28, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY2026 results delivered a top-line beat with revenue of $4.14B vs. $4.03B consensus, driven by a 43% YoY LC surge in innovative brands (AUSTEDO, AJOVY, UZEDY). Despite the revenue beat, Normalized EPS of $0.02 significantly missed the $0.11 consensus due to a $726M acquisition charge for Emalex recorded in Q2. Management raised full-year FY26 revenue guidance for all three innovative brands while maintaining consolidated EPS and FCF outlooks, absorbing the Emalex impact.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Teva Pharmaceutical Industries(TEVA) the Revenue is 4.142 B (-0.81%), Beat estimate;the EBIT is 375 M (-66.9%), Beat estimate;the EPS is -0.49 (-296%), Miss estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

4.14B0.81%

4.03B3.51%

+0.11B2.70%

EBITExceed expectations

0.38B66.90%

0.32B71.34%

+0.05B4.44%

EPSMiss expectations

-0.49296.00%

-0.1458158.31%

-0.3442137.69%

Upcoming earnings report - Q3 FY2026

Available dateNov 3, 2026

Estimate Revenue$4.241 B

Estimate EBIT$1.209 B

Estimate EPS$0.2966

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly